Skinvisible, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019
May 24, 2019 at 09:24 pm IST
Share
Skinvisible, Inc. announced earnings results for the first quarter ended March 31, 2019. For the first quarter, the company announced sales was USD 8,367 compared to USD 15,632 a year ago. Operating loss was USD 146,092 compared to USD 174,566 a year ago. Net loss was USD 343,099 compared to net income of USD 96,530 a year ago. Basic loss per share from continuing operations was USD 0.12 compared to basic earnings per share from continuing operations of USD 0.01 a year ago.
Skinvisible, Inc., through its wholly owned subsidiary Skinvisible Pharmaceuticals Inc., is a pharmaceutical research and development (R&D) company. The Company is engaged in developing and patenting a polymer delivery system, Invisicare, and formulating over forty topical skin products. Its flagship product, Pivotal, is a patented polymer delivery system technology, Invisicare. Invisicare is a patented polymer delivery system that enhances the delivery of active ingredients for topically applied skin care products. Its patented technology has a formula and process for combining active ingredients with a delivery system that extends the duration of time the product remains on the skin and active. Invisicare is specifically formulated to carry water-insoluble active and certain cationic active ingredients in water-based products without the use of alcohol, silicones, waxes, or other organic solvents. It is also exploring opportunities in medical markets outside the dermatology market.
SKINVISIBLE, INC. 